Biocon’s arm gets tentative nod for Rifaximin Tablets, 550 mg

07 Oct 2025 Evaluate

Biocon’s wholly owned subsidiary -- Biocon Pharma in partnership with Carnegie Pharmaceuticals LLC, received tentative approval from the U.S. Food and Drug Administration (USFDA) for the ANDA for Rifaximin Tablets, 550 mg.

Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy (HE) recurrence and to treat irritable bowel syndrome with diarrhea (IBS-D) in adults.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

390.10 -5.15 (-1.30%)
29-Dec-2025 15:14 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1715.40
Dr. Reddys Lab 1267.95
Cipla 1495.10
Zydus Lifesciences 905.10
Lupin 2082.20
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×